Shots:

• The NDA submission was submitted to NMPA’s CDE and is based on P-III VICTORIA study- seeking regulatory approval of vericiguat in China
• In Oct’2014- Bayer and MSD signed a WW agreement for sGC modulators. The therapy is being jointly developed by both the companies as per the collaboration and has received the US FDA’s PR in Jul’2020
• Vericiguat (BAY 1021189/ MK-1242) is an sGC-stimulator being developed to treat patients with symptomatic CHF with an ejection fraction less than 45% who have had a previous worsening HF event in combination with available HF therapies

­ Ref: Bayer| Image: Berkeleyside